Intellia Therapeutics (NTLA), a clinical-stage biotechnology company, saw its shares plunge more than 22% on Friday, Nov. 7, after management acknowledged a patient’s death in a gene-editing study for its lead candidate in the Q3 earnings release. The U.S. Food and Drug Administration (FDA) has also put the Phase 3 study on hold, causing the stock to fall just over 14% year to date.
Intellia develops in vivo CRISPR-based gene-editing therapies to treat or cure genetic diseases by precisely editing DNA directly inside the body. Meanwhile, Cathie Wood, known for her bold conviction in cutting-edge innovation, has been steadily increasing her stake in Intellia.
